← Leaderboards
Fang Wei
University Of California Los Angeles
$3,486,544
Attributed
$12,645,047
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,645,047 · 4
By mechanism
U01$7,881,432 · 1
R01$3,236,869 · 1
UH3$1,158,300 · 1
UH2$368,446 · 1
Top collaborators
- David T Wong13 shared
- Denise R Aberle8 shared
- Kostyantyn Krysan8 shared
- David S Chia5 shared
- Sherin U. Devaskar5 shared
- Guy Soo Hoo5 shared
- William Hsu3 shared
- Charles Martin Strom3 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Denise R Aberle$7,414,266
- Sherin U. Devaskar$31,339,941
- David T Wong$54,826,713
- Kostyantyn Krysan$1,523,760
- Alison Chu$3,092,687
Others in their field
Other Emerging Leaders on “Diagnosis”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$141,100,782
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
Research focus
DiagnosisDetectionPerformanceMeasurementTechnologyLiquid BiopsyProspectiveScreeningDiagnosticSymptomsBiological MarkersProceduresImageBloodBaseBlood SpecimenMicrornasValidationCancer DetectionMortalityNon-Small-Cell Lung CarcinomaElectric FieldMolecularMalignant Neoplasm Of Lung
Grant awards (18)
EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment$2,745,735
U01 · FY2025 · CA
EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment$878,436
U01 · FY2024 · CA
EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment$932,148
U01 · FY2023 · CA
Electrochemical Liquid Biopsy Assessing Placental Health$635,975
R01 · FY2023 · HD
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$647,157
U01 · FY2022 · CA
Electrochemical Liquid Biopsy Assessing Placental Health$635,975
R01 · FY2022 · HD
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$670,270
U01 · FY2021 · CA
Electrochemical Liquid Biopsy Assessing Placental Health$645,071
R01 · FY2021 · HD
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$390,000
UH3 · FY2021 · CA
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$669,593
U01 · FY2020 · CA
Electrochemical Liquid Biopsy Assessing Placental Health$658,236
R01 · FY2020 · HD
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$390,000
UH3 · FY2020 · CA
Electrochemical Liquid Biopsy Assessing Placental Health$661,612
R01 · FY2019 · HD
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$652,690
U01 · FY2019 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$378,300
UH3 · FY2019 · CA
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$685,403
U01 · FY2018 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$184,223
UH2 · FY2018 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$184,223
UH2 · FY2017 · CA